MannKind Corporation (MNKD) said on Wednesday that it has entered into up to $500 million strategic financing agreement with ...

MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

Good morning, and welcome to the MannKind Corporation Second Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded on August 6, 2025, and will be available for ...

Conference call today at 9:00 am ET2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD ...

MannKind (MNKD) delivered earnings and revenue surprises of -100.00% and -2.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

For the quarter ended June 2025, MannKind (MNKD) reported revenue of $76.53 million, up 5.7% over the same period last year. EPS came in at $0, compared to $0.05 in the year-ago quarter. The reported ...

Analysts anticipate MannKind to report an earnings per share (EPS) of $0.06. The announcement from MannKind is eagerly ...

The biopharmaceutical company posted adjusted earnings of $0.05 per share for the second quarter, matching analyst estimates. However, revenue came in at $76.53 million, below the consensus estimate ...

MannKind Corp (NASDAQ:MNKD) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for Q2 2025 revenue ...